Ono Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Ono Pharmaceutical CEO'su Gyo Sagara, Sep2008 tarihinde atandı, in görev süresi 15.33 yıldır. in toplam yıllık tazminatı ¥ 228.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 33.8% maaş ve 66.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.022% ine doğrudan sahiptir ve bu hisseler MX$ 31.93M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1 yıl ve 3.6 yıldır.

Anahtar bilgiler

Gyo Sagara

İcra Kurulu Başkanı

JP¥228.0m

Toplam tazminat

CEO maaş yüzdesi	33.8%
CEO görev süresi	15.3yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Gyo Sagara'un ücretlendirmesi Ono Pharmaceutical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2023	n/a	n/a	JP¥125b
Jun 30 2023	n/a	n/a	JP¥115b
Mar 31 2023	JP¥228m	JP¥77m	JP¥113b

Tazminat ve Piyasa: Gyo 'nin toplam tazminatı ($USD 1.57M ), MX pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 2.38M ).

Tazminat ve Kazançlar: Gyo şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Gyo Sagara (65 yo)

15.3yrs

Görev süresi

JP¥228,000,000

Tazminat

Mr. Gyo Sagara has been the President and Chief Executive Officer at Ono Pharmaceutical Co., Ltd since September 2008 and serves as it’s Director. Mr. Sagara served as a Director of Marketing Headquarters...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gyo Sagara	CEO, President & Representative Director	15.3yrs	JP¥228.00m	0.022% MX$ 31.9m
Masaki Ito	Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning	less than a year	Veri yok	Veri yok
Takehiro Yamada	Corporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion Office	less than a year	Veri yok	Veri yok
Masayuki Tanigawa	Corporate Officer & Executive Director of Corporate Development & Strategy	less than a year	Veri yok	Veri yok
Toichi Takino	Senior Managing Executive Officer	2.6yrs	Veri yok	0.0046% MX$ 6.8m
Toshihiro Tsujinaka	Sr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and Director	less than a year	Veri yok	0.0044% MX$ 6.5m
Hiromu Habashita	Corporate Officer	no data	Veri yok	Veri yok
Kiyoaki Idemitsu	Managing Executive Officer	no data	Veri yok	0.0021% MX$ 3.1m
Shinji Takai	Corporate Officer & Head of Medical Affairs	no data	Veri yok	Veri yok
Satoshi Takahagi	Corporate Officer and Executive Director of Sales	no data	Veri yok	Veri yok
Satoshi Numata	Corp. Exe. Officer and Exe. Dir. of Digital & IT Strategy	2yrs	Veri yok	Veri yok
Akira Takada	Corporate Officer and Executive Director of CMC & Production	no data	Veri yok	Veri yok

1.0yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: 4528 N 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gyo Sagara	CEO, President & Representative Director	no data	JP¥228.00m	0.022% MX$ 31.9m
Toichi Takino	Senior Managing Executive Officer	3.6yrs	Veri yok	0.0046% MX$ 6.8m
Toshihiro Tsujinaka	Sr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and Director	3.6yrs	Veri yok	0.0044% MX$ 6.5m
Kiyoaki Idemitsu	Managing Executive Officer	2.6yrs	Veri yok	0.0021% MX$ 3.1m
Masao Nomura	Independent Outside Director	5.6yrs	Veri yok	0.0010% MX$ 1.6m
Shusaku Nagae	Independent Outside Director	2.6yrs	Veri yok	Veri yok
Katsuyoshi Nishimura	Chairman of Audit & Supervisory Board	12.6yrs	Veri yok	0.0025% MX$ 3.7m
Akiko Tanabe	Outside Audit & Supervisory Board Member	3.6yrs	Veri yok	Veri yok
Yasuo Hishiyama	Outside Audit & Supervisory Board Member	7.6yrs	Veri yok	Veri yok
Akiko Okuno	Independent Outside Director	3.6yrs	Veri yok	Veri yok
Hironobu Tanisaka	Outside Audit Supervisory Board Member	2.6yrs	Veri yok	0.00021% MX$ 311.4k

3.6yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4528 N 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

Ono Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Ono Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 03, 2025

Ono Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024

Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL

Ono Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 01, 2023

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 19,000,000 shares, representing 3.89% for ¥50,000 million.

Ono Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Upcoming dividend of JP¥33.00 per share at 2.4% yield

Third quarter 2023 earnings released: EPS: JP¥68.23 (vs JP¥36.83 in 3Q 2022)

Ono Pharmaceutical Co., Ltd. (TSE:4528) acquired Research assets related to multiple research-stage oncology programs from KSQ Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥67.30 (vs JP¥44.51 in 2Q 2022)

Upcoming dividend of JP¥33.00 per share

Ono Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings released: EPS: JP¥60.37 (vs JP¥48.23 in 1Q 2022)

Less than half of directors are independent

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş